(CIDRAP News) – Some professional groups and scientists think it's a good idea to classify highly pathogenic avian (HPAI) H5N1 influenza viruses as "select agents" requiring special research precautions, while others say the step is unnecessary and would impede research, according to comments they have filed with the US Department of Health and Human Services (HHS).
(CIDRAP News) – As a meeting to discuss issues related to federally funded H5N1 avian influenza research wrapped up today, experts anticipated that a voluntary moratorium on work with lab-modified strains that have increased transmissibility might end soon and said they sensed agreement about lab biosecurity levels.
(CIDRAP News) – Federal health officials are in the midst of crafting a framework for funding H5N1 avian influenza gain-of-function studies, and today at a workshop they heard varied feedback from researchers, biosecurity experts, and others.
(CIDRAP News) – With tougher security requirements set to take effect next April, few state public health laboratories plan to maintain stocks of certain pathogens considered most tempting to bioterrorists, according to the Association of Public Health Laboratories (APHL) and officials with state labs.
(CIDRAP News) – A new report from the US Department of Health and Human Services (HHS) offers a few predictions on when certain new countermeasures against biological threats will become available, including a forecast for two novel influenza drugs and possibly a next-generation anthrax vaccine within the next 5 years.
(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the nation's first cell-based flu vaccine, a product from Novartis that uses technology that could help vaccinate more Americans in a pandemic but still has many of the same limitations of older egg-based flu vaccines.
(CIDRAP News) – A government advisory committee yesterday endorsed the safety and immunogenicity of an adjuvant-containing H5N1 influenza vaccine proposed for inclusion in the US pandemic emergency stockpile, signaling that it could become the first adjuvanted flu vaccine to win approval in the United States.